AIM ImmunoTech Files Definitive Proxy Materials

TL;DR

AIM ImmunoTech filed its final proxy statement on Nov 8, 2024. Shareholders vote soon.

AI Summary

AIM ImmunoTech Inc. filed a Definitive Additional Materials proxy statement on November 8, 2024. This filing relates to the company's proxy statement and is not a preliminary filing. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and its fiscal year ends on December 31st.

Why It Matters

This filing indicates that AIM ImmunoTech is proceeding with its shareholder meeting and related proposals, which could impact corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — This is a routine filing of proxy materials, not indicating any immediate financial or operational risk.

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Registrant
• Hemispherx Biopharma Inc. (company) — Former company name
• 20241108 (date) — Filing date

FAQ

Filing Documents

• formdefa14a.htm (DEFA14A) — 22KB
• ex1_001.jpg (GRAPHIC) — 438KB
• ex1_002.jpg (GRAPHIC) — 454KB
• ex1_003.jpg (GRAPHIC) — 416KB
• 0001493152-24-044349.txt ( ) — 1825KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 AIM ImmunoTech Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 On November 8, 2024, AIM ImmunoTech Inc. (the “Company”) issued the following materials, copies of which are attached hereto as Exhibit 1. Important Additional Information The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here . Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/. Exhibit 1

View Full Filing

View this DEFA14A filing on SEC EDGAR